PolyGone launched a microplastic analysis lab, creating a new revenue stream separate from its filtration hardware. This service caters to companies wanting to validate "microplastic-free" claims, establishing PolyGone as a market authority while its core technology scales.

With no regulations forcing microplastic removal, PolyGone struggled to find municipal customers. Success came from partnering with one utility that acted as a "co-developer," providing crucial feedback to move the product from lab to industrial scale.

Instead of landfilling captured plastic fragments, PolyGone partners with other firms to upcycle them. Through enzymatic or catalytic conversion, the degraded plastic is transformed into non-plastic compounds, creating a potential feedstock for industries like pharmaceuticals or fuels.

Instead of forcing a microbe to create a foreign product through extensive engineering, first identify what it is predisposed to make. Then, apply minimal genetic "nudges" to optimize existing pathways. This "downhill" approach creates a much more efficient and viable R&D process.

The company's platform creates drug microparticles large enough for tumor retention but with a massive surface area for sustained drug release. This is counterintuitive to typical engineering, where surface area is increased by making particles smaller, and it forms the basis of their intellectual property.

Industrial biotech startups often fail trying to scale cost-effectively. Since customers rarely pay a premium for sustainability alone, directly replacing a cheap petrochemical is a losing battle. A better strategy is to develop unique products with novel functionalities.

The founder, an architectural designer, applied design principles typically used for glamorous city projects to overlooked areas like waste management. This unique perspective led to a novel approach for capturing microplastics, a problem traditionally left to scientists.

When faculty told the architecture-trained founders they lacked the scientific skills to tackle microplastics, they proactively partnered with students and professors in chemistry and engineering. This cross-disciplinary collaboration was essential for developing their first prototype.

PolyGone's founders resisted the urge to perfect their filter in the lab when it only had 25% efficacy. Pushed by a co-founder, they deployed it early, enabling rapid, real-world iteration that ultimately led to 98% efficiency and commercial traction.